Xenetic Biosciences (XBIO) Gross Margin (2011 - 2017)
Xenetic Biosciences' (XBIO) quarterly Gross Margin came in at 14.15% in Q3 2017, down 118.92% on a QoQ basis from 74.81% in Q2 2013.
Xenetic Biosciences (XBIO) Gross Margin (2011 - 2017) Analysis & Trends
Xenetic Biosciences (XBIO) has 4 years of Gross Margin data on file, last reported at 14.15% in Q3 2017.
- Quarterly Gross Margin changed N/A year-over-year to 14.15% in Q3 2017, while the trailing twelve-month figure through Sep 2018 was 0.11% (down 68.0% YoY) and the FY2013 annual result came in at 100.0%, up 1527.0% from the prior year.
- Gross Margin slipped to 14.15% in Q3 2017, from 74.81% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 89.24% in Q1 2013 to a low of 14.15% in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | Xenetic Biosciences | 7.59 Mn | 1.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | -14.15% |
| May 31, 2013 | 74.81% |
| Feb 28, 2013 | 89.24% |
| Nov 30, 2012 | 63.79% |
| May 31, 2012 | 100.00% |
| Feb 29, 2012 | 76.03% |
| Nov 30, 2011 | 89.70% |